flow trial semaglutide trial: In participants with type 2 diabetes and chronic kidney disease, weekly treatment substantially reduced risks of heart failure events or cardiovascular death. https://t.co/SaGx7tf0ie #JACC #ESCCongress #HeartFailure #T2D #CKD Semaglutide in CKD? Check out

J Clin Invest (2005) 115(2):40717

Earlier this month, (June 2025), Novo inked a deal worth up to $815 million with Deep Apple Therapeutics, a South San Francisco-based company specializing in small-molecule drug discovery to discover, develop, and commercialize oral small-molecule therapeutics directed at a non-incretin G protein-coupled receptors (GPCR) target for cardiometabolic diseases, including obesity, in a deal worth up to $812 million

Avoid air fresheners, as they can worsen histamine intolerance

Sudden discontinuation of beta-blockers can lead to a dangerous rebound effect in heart rate and blood pressure